Christine Tagayun
Cornea and External Diseases Specialist · Mc Lean, VANPI 1952747289
Payments from drug & device makers
Across 225 payments — averaging $98.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$12K
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Harrow Eye, LLC$2K
- AbbVie$2K
- Dompe US, Inc.$469
- plus $2K from 19 others
What the payments were for
- Consulting fees$8,18839%
- Speaking & faculty fees$1,4007%
- Travel & lodging$4,73723%
- Food & beverage$6,68132%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 21 | $12,248 |
| Alcon | 18 | $2,214 |
| Johnson & Johnson Surgical Vision, Inc. | 16 | $1,858 |
| Harrow Eye, LLC | 11 | $1,762 |
| AbbVie(2 entities) | 70 | $1,555 |
| Dompe US, Inc. | 11 | $469 |
| Bausch & Lomb Americas Inc. | 12 | $316 |
| Sun Pharmaceutical Industries Inc. | 12 | $314 |
| Kala Pharmaceuticals, Inc. | 9 | $286 |
| Novartis | 10 | $201 |
| Tarsus Pharmaceuticals, Inc. | 4 | $133 |
| Aerie Pharmaceuticals, Inc. | 1 | $125 |
| Biotissue Holdings Inc. | 6 | $114 |
| Astellas Pharma US Inc | 1 | $105 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $95 |
| Rxsight Inc | 2 | $66 |
| Amgen(2 entities) | 3 | $61 |
| Sight Sciences, Inc. | 3 | $61 |
| NEW World Medical,inc. | 2 | $59 |
| Oyster Point Pharma, Inc. | 2 | $45 |
| Omeros Corporation | 2 | $37 |
| Sanofi | 1 | $28 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$7,683
- Tecnis IOL$3,450
- Travoprost Intraocular Implant - iDose$2,902
- LenSx$1,676
- VEVYE$1,521
- Tecnis Simplicity$1,205
- STAR S4 IR$297
- VERITAS Vision System$150
- Rhopressa$125
- Rocklatan$125
- INVELTYS$125
- Oxervate$120
- ReSTOR$120
- iDose$112
- DURYSTA$112
- Clareon$111
- iDoseTR$110
- LUMIGAN$109
How this compares
Too few cornea and external diseases specialist providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $637,570 |
| RestasisCyclosporine | 86 | $119,165 |
| XiidraLifitegrast | 34 | $61,614 |
| Cyclosporine | 44 | $17,117 |
| CequaCyclosporine | 13 | $10,227 |
| Loteprednol Etabonate | 26 | $7,347 |
| LumiganBimatoprost | 12 | $7,205 |
| Prednisolone Acetate | 171 | $6,190 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $5,621 |
| Travoprost | 16 | $5,147 |
| Timolol Maleate | 43 | $2,642 |
| Brimonidine Tartrate | 26 | $2,605 |
| ValacyclovirValacyclovir Hcl | 19 | $1,454 |
| Latanoprost | 124 | $1,433 |
| Gatifloxacin | 35 | $1,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $469 | $637,57012 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,555 | $131,990116 claims |
| Bausch & Lomb Americas Inc.Xiidra | $316 | $61,61434 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $314 | $10,22713 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $95 | $7,34726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Mc Lean
- Sylvia Casas de LeonReston$4K
- Zachary SkurskiFort Belvoir$2K
- Jason GoldbergHampton$485
- Donna BrownRichmond$346
- Bryan GoldmanHenrico$144
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.